Skip to main content
SpringerLink
Log in

Immunisation

  • Chapter
  • First Online:
Manual of Travel Medicine

  • 625 Accesses

Abstract

Immunisation is a key strategy in the prevention of infectious diseases, both at an individual and community (public health) level. Vaccine choice and priorities for the traveller vary according to the characteristics of the individual and their planned trip, and should be individualised. Clinicians should take into consideration the range of potential variations on a planned trip as itineraries can change. Because many vaccines provide a period of protection that extends well beyond an individual trip, it is worthwhile to discuss travellers’ future plans and consider the cumulative risk of disease exposure when weighing up the risks and benefits of vaccination. In this chapter we provide a general discussion of vaccine choice and priorities for the traveller relative to required, recommended and routine vaccinations and a detailed discussion of all vaccines that may be relevant for travellers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Key Reading

2.1 Introduction to Pre-travel Vaccination

2.2 Cholera

2.3 Diphtheria and Tetanus

  • Demicheli V, Barale A, Rivetti A. Vaccines for women for preventing neonatal tetanus. Cochrane Database Syst Rev. 2015;(7):CD002959.

    Google Scholar 

  • Murphy T, Slade B, Broder K, Kretsinger K, et al. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-4):1–51.

    PubMed  Google Scholar 

  • National Notifiable Diseases Surveillance System. Australian Government Department of Health. http://www9.health.gov.au/cda/source/cda-index.cfm.

  • NNDSS Annual Report Working Group. Australia’s notifiable disease status, 2014: Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell Q Rep. 2016;40:E48–145.

    Google Scholar 

  • Sadoh A, Oladokun R. Re-emergence of diphtheria and pertussis: implications for Nigeria. Vaccine. 2012;30:7221–8.

    Article  CAS  PubMed  Google Scholar 

  • Thwaites C, Loan H. Eradication of tetanus. Br Med Bull. 2015;116:69–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zakikhany K, Efstratiou A. Diphtheria in Europe: current problems and new challenges. Future Microbiol. 2012;7:595–607.

    Article  PubMed  Google Scholar 

2.4 Hepatitis A

  • Averhoff FM, Khudyakov Y, Nelson NP. Hepatitis A vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. 7th ed. Philadelphia: Elsevier; 2018. p. 177–204.

    Google Scholar 

  • Crofts N, Cooper G, Stewart T, Kiely I, et al. Exposure to hepatitis A virus among blood donors, injecting drug users and prison entrants in Victoria. J Viral Hepat. 1997;4(5):333–8.

    Article  CAS  PubMed  Google Scholar 

  • Hanna JN, Hills SL, Humphreys JL. Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in north Queensland. Med J Aust. 2004;181:482–5.

    Article  PubMed  Google Scholar 

  • Innis B, Snitbhan R, Kinasol P, Laorakpongse T, et al. Protection against hepatitis A by an inactivated vaccine. JAMA. 1994;271:1328–34.

    Article  CAS  PubMed  Google Scholar 

  • Lange WR, Frame JD. High incidence of viral hepatitis among American missionaries in Africa. Am J Trop Med Hyg. 1990;43(5):527–33.

    Article  CAS  PubMed  Google Scholar 

  • Lau C, Streeton C, David M, Sly P, Mills D. The tolerability of a combined hepatitis A and typhoid vaccine in children aged 2-16 years: an observational study. J Travel Med. 2016;23:tav023.

    Article  PubMed  Google Scholar 

  • Mutsch M, Spicher VM, Gut C, Steffen R. Hepatitis A virus infections in travelers, 1988–2004. Clin Infect Dis. 2006;42:490–7.

    Article  PubMed  Google Scholar 

  • Nelson N, Hepatitis A. In: Centers for Disease Control and Prevention. CDC Yellow Book 2018: Health Information for International Travel. New York: Oxford University Press; 2017. Updated 9 Sep 2017. https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/hepatitis-a. Accessed 24 Dec 2018.

    Google Scholar 

  • Proell S, Maiwald H, Nothdurft H-D, Saenger R, et al. Combined vaccination against hepatitis A, hepatitis B, and typhoid fever: safety, reactogenicity, and immunogenicity. J Travel Med. 2002;9:122–6.

    Article  PubMed  Google Scholar 

  • Rendi-Wagner P, Kundi M, Stemberger H, Wiedermann G, et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine. 2001;19(15–16):2055–60.

    Article  CAS  PubMed  Google Scholar 

  • Thompson C, Dey A, Fearnley E, Polkinghorne B, Beard F. Impact of the national targeted hepatitis A immunisation program in Australia: 2000-2014. Vaccine. 2017;35:170–6.

    Article  PubMed  Google Scholar 

  • Victor JC, Monto AS, Surdina TY, Suleimenova SZ, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med. 2007;357:1685–94.

    Article  CAS  PubMed  Google Scholar 

  • Werzberger A, Mensch B, Kuter B, Brown L, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med. 1992;327:453–7.

    Article  CAS  PubMed  Google Scholar 

  • World Health Organization. Hepatitis A vaccines. WHO position paper. Wkly Epidemiol Rec. 2012;87(28-9):261–76.

    Google Scholar 

2.5 Hepatitis B

  • Averhoff F. Hepatitis B [updated 13 June 2017]. In: Centers for Disease Control and Prevention. CDC Yellow Book 2018: Health Information for International Travel. New York: Oxford University Press; 2017. https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/hepatitis-b. Accessed 24 Dec 2018.

    Google Scholar 

  • Banatvala J, van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 2000;19:877–85.

    Article  CAS  PubMed  Google Scholar 

  • Johnson DF, Leder K, Torresi J. Hepatitis B and C infection in international travelers. J Travel Med. 2013;20(3):194–202.

    Article  PubMed  Google Scholar 

  • Johnson DF, Ratnam I, Matchett E, et al. The incidence of HBV and HCV infection in Australian travelers to Asia. J Travel Med. 2013;20(3):203–5.

    Article  PubMed  Google Scholar 

  • Leggat PA, Zwar NA, Hudson BJ. Hepatitis B risks and immunisation coverage amongst Australians travelling to Southeast Asia and East Asia. Travel Med Infect Dis. 2009;7:344–9.

    Article  PubMed  Google Scholar 

  • Rendi-Wagner P, Kundi M, Stemberger H, Wiedermann G, et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine. 2001;19(15–16):2055–60.

    Article  CAS  PubMed  Google Scholar 

  • Streeton CL, Zwar N. Risk of exposure to hepatitis B and other blood-borne viruses among Australians who travel abroad. J Travel Med. 2006;6:345–50.

    Article  Google Scholar 

  • Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. 7th ed. Philadelphia: Elsevier; 2018. p. 342–74.

    Chapter  Google Scholar 

  • World Health Organization. Hepatitis B vaccines. WHO Position Paper. Wkly Epidemiol Rec. 2017;92(27):369–92.

    Google Scholar 

  • Zuckerman JN, Steffen R. Risks of hepatitis B in travellers as compared to immunisation status. J Travel Med. 2000;7:170–4.

    Article  CAS  PubMed  Google Scholar 

  • Zwar NA, on behalf of the Travel Health Advisory Group. Hepatitis risk and vaccination among Australian travellers overseas. Med J Aust. 2003;178:469–70.

    Article  PubMed  Google Scholar 

2.6 Influenza

  • Ahmed F, Singleton JA, Franks AL. Influenza vaccination for healthy young adults. N Engl J Med. 2001;345(21):1543–7.

    Article  CAS  PubMed  Google Scholar 

  • Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA Guidelines - Vaccination of the egg-allergic individual. 2017. https://www.allergy.org.au/hp/papers/vaccination-of-the-egg-allergic-individual.

  • Australian Government Department of Health. Australian Influenza Surveillance Report—2018 National Influenza Season Summary. Canberra; 2018. http://www.health.gov.au/flureport#current.

  • Bridges CB, Fukuda K, Cox NJ, Singleton JA. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunisation Practices (ACIP). MMWR Recomm Rep. 2001;50:1–44.

    CAS  PubMed  Google Scholar 

  • Couch RB. Prevention and treatment of influenza. N Engl J Med. 2000;343(24):1778–87.

    Article  CAS  PubMed  Google Scholar 

  • Chen LH, Wilson ME. Recent advances and new challenges in travel medicine. Curr Infect Dis Rep. 2002;4(1):50–8.

    Article  PubMed  Google Scholar 

  • Mutsch M, Tavernini M, Marx A, Gregory V, et al. Influenza virus infection in travelers to tropical and subtropical countries. Clin Infect Dis. 2005;40:1282–7.

    Article  PubMed  Google Scholar 

  • Ratnam I, Black J, Leder K, Biggs BA, Gordon I, Matchett E, et al. Incidence and risk factors for acute respiratory illnesses and influenza virus infections in Australian travellers to Asia. J Clin Virol. 2013;57(1):54–8.

    Article  PubMed  Google Scholar 

2.7 Japanese Encephalitis (JE)

  • Bonaparte M, Dweik B, Feroldi E, Meric C, Bouckenooghe A, Hildreth S, et al. Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India. BMC Infect Dis. 2014;14:156.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Burchard GD, Caumes E, Connor BA, Freedman DO, Jelinek T, Jong EC, et al. Expert opinion on vaccination of travelers against Japanese encephalitis. J Travel Med. 2009;16(3):204–16.

    Article  PubMed  Google Scholar 

  • Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89(10):766–74. 74A-74E.

    Article  PubMed  PubMed Central  Google Scholar 

  • Chokephaibulkit K, Houillon G, Feroldi E, Bouckenooghe A. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV(R)) in children. Expert Rev Vaccines. 2016;15(2):153–66.

    Article  CAS  PubMed  Google Scholar 

  • Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, Sabchareon A, et al. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr Infect Dis J. 2010;29(12):1111–7.

    Article  PubMed  Google Scholar 

  • Cramer JP, Jelinek T, Paulke-Korinek M, Reisinger EC, Dieckmann S, Alberer M, et al. One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series. J Travel Med. 2016;23(3):1–8.

    Google Scholar 

  • Desai K, Coudeville L, Bailleux F. Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine. Vaccine. 2012;30(15):2510–5.

    Article  CAS  PubMed  Google Scholar 

  • Erra EO, Kantele A. The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis. Expert Rev Vaccines. 2015;14(9):1167–79.

    Article  CAS  PubMed  Google Scholar 

  • Gao X, Li X, Li M, Fu S, Wang H, Lu Z, et al. Vaccine strategies for the control and prevention of Japanese encephalitis in Mainland China, 1951-2011. PLoS Negl Trop Dis. 2014;8(8):e3015.

    Article  PubMed  PubMed Central  Google Scholar 

  • Guy B, Guirakhoo F, Barban V, Higgs S, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010;28(3):632–49.

    Article  CAS  PubMed  Google Scholar 

  • Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973–2008. Am J Trop Med Hyg. 2010;82(5):930–6.

    Article  PubMed  PubMed Central  Google Scholar 

  • Halstead SB, Hills SL, Dubischar K. Japanese encephalitis vaccines. Chapter 33. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 7th ed. Philadelphia: Elsevier Saunders; 2018. p. 511–48.

    Google Scholar 

  • Hills SL, Rabe IB, Fischer M. Japanese Encephalitis [updated May 31 2017]. In: Centers for Disease Control and Prevention. CDC Yellow Book 2018: Health Information for International Travel. New York: Oxford University Press; 2017. https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/japanese-encephalitis. Accessed 24 Dec 2018.

    Google Scholar 

  • Kaltenböck A, Dubischar-Kastner K, Eder G, Jilg W, et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX 1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study. Vaccine. 2009;27(33):4483–9.

    Article  PubMed  CAS  Google Scholar 

  • Lehtinen VA, Huhtamo E, Siikamaki H, Vapalahti O. Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand. J Clin Virol. 2008;43(1):93–5.

    Article  PubMed  Google Scholar 

  • Nasveld PE, Ebringer A, Elmes N, Bennett S, Yoksan S, Aaskov J, et al. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults. Hum Vaccin. 2010;6(12):1038–46.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ratnam I, Leder K, Black J, Biggs BA, Matchett E, Padiglione A, et al. Low risk of Japanese encephalitis in short-term Australian travelers to Asia. J Travel Med. 2013;20(3):206–8.

    Article  PubMed  Google Scholar 

  • Schuller E, Jilma B, Voicu V, Golor G, et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine. 2008;26:4382–6.

    Article  CAS  PubMed  Google Scholar 

  • Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet. 2007;370:1847–53.

    Article  CAS  PubMed  Google Scholar 

  • Torresi J, McCarthy K, Feroldi E, Méric C. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials. Vaccine. 2010;28(50):7993–8000.

    Article  CAS  PubMed  Google Scholar 

2.8 MMR

  • Aickin R, Hill D, Kemp A. Measles immunisation in children with allergy to egg. BMJ. 1994;309:223–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Grant G, Reef S, Dabbagh A, Gacic-Dobo M, Strebel P. Global progress toward Rubella and Congenital Rubella syndrome control and elimination—2000-2014. Morb Mortal Wkly Rep. 2015;64:1052–5.

    Article  Google Scholar 

  • Ramanathan R, Voigt E, Kennedy R, Poland G. Knowledge gaps persist and hinder progress in eliminating mumps. Vaccine. 2018;36:3721–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

2.9 Meningococcal Disease

  • Borrow R, Alarcón P, Carlos J, Caugant DA, Christensen H, Debbag R, De Wals P, Echániz-Aviles G, Findlow J, Head C, Holt D, Kamiya H, Saha SK, Sidorenko S, Taha MK, Trotter C, Vázquez Moreno JA, von Gottberg A, Sáfadi MA, Global Meningococcal Initiative. The Global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16:313–28.

    Article  CAS  PubMed  Google Scholar 

  • Borrow R, Caugant DA, Ceyhan M, Christensen H, Dinleyici EC, Findlow J, Glennie L, Von Gottberg A, Kechrid A, Vázquez Moreno J, Razki A, Smith V, Taha MK, Tali-Maamar H, Zerouali K, Global Meningococcal Initiative (GMI). Meningococcal disease in the Middle East and Africa: findings and updates from the Global Meningococcal Initiative. J Infect. 2017;75:1–11.

    Article  PubMed  Google Scholar 

  • Cohn A, MacNeil J, Clark T, Ortega-Sanchez I, Briere E, Meissner H, Baker C, Messonnier N, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1–28.

    PubMed  Google Scholar 

  • Cramer J, Wilder-Smith A. Meningococcal disease in travelers: update on vaccine options. Curr Opin Infect Dis. 2012;25:507–17.

    Article  PubMed  Google Scholar 

  • McCarthy A, Committee to Advise on Tropical Medicine; Travel (CATMAT). Statement on meningococcal disease and the International Traveller. Can Commun Dis Rep. 2015;41:100–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

2.10 Pertussis

  • Edwards K, Berbers G. Immune responses to pertussis vaccines and disease. J Infect Dis. 2014;209(Suppl 1):S10–5.

    Article  CAS  PubMed  Google Scholar 

  • Elliott E, McIntyre P, Ridley G, Morris A, et al. National study of infants hospitalised with pertussis in the acellular vaccine era. Pediatr Infect Dis J. 2004;23:246–52.

    Article  PubMed  Google Scholar 

  • Lambert L. Pertussis vaccine trials in the 1990s. J Infect Dis. 2014;209(Suppl 1):S4–9.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lapidot R, Gill C. The Pertussis resurgence: putting together the pieces of the puzzle. Trop Dis Travel Med Vaccin. 2016;2:26.

    Article  Google Scholar 

  • Pillsbury A, Quinn H, McIntyre P. Australian vaccine preventable disease epidemiological review series: pertussis, 2006-2012. Commun Dis Intell Q Rep. 2014;38:E179–94.

    PubMed  Google Scholar 

  • Prevention and Control of Pertussis. J Infect Dis. 2014;209(Suppl 1).

    Article  Google Scholar 

  • Straney L, Schibler A, Ganeshalingham A, Alexander J, Festa M, Slater A, MacLaren G, Schlapbach L, Australian and New Zealand Intensive Care Society Centre for Outcomes and Resource Evaluation and the Australian and New Zealand Intensive Care Society Paediatric Study Group. Burden and outcomes of severe pertussis infection in critically ill infants. Pediatr Crit Care Med. 2016;17:735–42.

    Article  PubMed  Google Scholar 

  • Wilder-Smith A, Earnest A, Ravindran S, Paton N. High incidence of pertussis among Hajj pilgrims. Clin Infect Dis. 2003;37:1270–2.

    Article  PubMed  Google Scholar 

  • World Health Organization. Pertussis vaccine: WHO position paper—August 2015. Wkly Epidemiol Rec. 2015;90(35):433–60.

    Google Scholar 

  • Yeung K, Duclos P, Nelson E, Hutubessy R. An update of the global burden of pertussis in children younger than 5 years: a modelling study. Lancet Infect Dis. 2017;17:974–80.

    Article  PubMed  Google Scholar 

2.11 Pneumococcal Disease

  • Black S, Shinefield H, Fireman B, Lewis E, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187–95.

    Article  CAS  PubMed  Google Scholar 

  • Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–25.

    Article  CAS  PubMed  Google Scholar 

  • Dagan R, Frasch C. Clinical characteristics of a novel 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine candidate (PHiD-CV). Pediatr Infect Dis J. 2009;28(4 Suppl):S63–118.

    Article  PubMed  Google Scholar 

  • Ewald H, Briel M, Vuichard D, Kreutle V, Zhydkov A, Gloy V. The clinical effectiveness of pneumococcal conjugate vaccines: a systematic review and meta-analysis of randomized controlled trials. Dtsch Arztebl Int. 2016;113(9):139–46.

    PubMed  PubMed Central  Google Scholar 

  • Gidding HF, McCallum L, Fathima P, Moore HC, Snelling TL, Blyth CC, et al. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia. Vaccine. 2018;36(19):2650–6.

    Article  CAS  PubMed  Google Scholar 

  • Isturiz RE, Schmoele-Thoma B, Scott DA, Jodar L, Webber C, Sings HL, et al. Pneumococcal conjugate vaccine use in adults. Expert Rev Vaccines. 2016;15(3):279–93.

    Article  CAS  PubMed  Google Scholar 

  • Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, et al. Long-term impact of a “3 + 0” schedule for 7- and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in Australia, 2002-2014. Clin Infect Dis. 2017;64(2):175–83.

    Article  PubMed  Google Scholar 

  • Lucero MG, Dulalia VE, Nillos LT, Williams G, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009;(4):CD004977.

    Google Scholar 

  • Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-11):1–18.

    PubMed  Google Scholar 

  • Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines. 2011;10:307–22.

    Article  CAS  PubMed  Google Scholar 

  • Russell FM, Carapetis JR, Balloch A, Licciardi PV, et al. Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine. 2010;28:3341–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Scott J. The preventable burden of pneumococcal disease in the developing world. Vaccine. 2007;25:2398–405.

    Article  CAS  PubMed  Google Scholar 

  • Tin Tin Htar M, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis. 2015;15:419.

    Article  PubMed  PubMed Central  Google Scholar 

  • Torzillo PJ, Morey F, Gratten M, Murphy D, et al. Changing epidemiology of invasive pneumococcal disease in central Australia prior to conjugate vaccine: a 16-year study. Vaccine. 2007;25:2375–8.

    Article  PubMed  Google Scholar 

2.12 Poliomyelitis

  • Stewardson AJ, Roberts JA, Beckett CL, et al. Imported case of poliomyelitis, Melbourne, Australia, 2007. Emerg Infect Dis. 2009;15:63–5.

    Article  PubMed  PubMed Central  Google Scholar 

  • Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine—live. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Vaccines. 7th ed. Philadelphia: Elsevier; 2018. p. 866–917.

    Google Scholar 

  • Vidor E. Poliovirus vaccine—inactivated. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. 7th ed. Philadelphia: Elsevier; 2018. p. 841–65.

    Chapter  Google Scholar 

  • Wilder-Smith A, Leong WY, Lopez LF, et al. Potential for international spread of wild poliovirus via travelers. BMC Med. 2015;13:133.

    Article  PubMed  PubMed Central  Google Scholar 

  • World Health Organization (WHO). Polio vaccine: WHO position paper—March, 2016. Wkly Epidemiol Rec. 2016;91(12):145–68.

    Google Scholar 

  • World Health Organization (WHO). Polio: statement of the twenty-first IHR Emergency Committee regarding the international spread of poliovirus. 29 May 2019. https://www.who.int/news-room/detail/29-05-2019-statement-of-thetwenty-first-ihr-emergency-committee. Accessed 11 June 2019.

2.13 Rabies

2.14 Rotavirus Infection

  • Carlin JB, Macartney KK, Lee KJ, et al. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia’s National Immunisation Program. Clin Infect Dis. 2013;57:1427–34.

    Article  PubMed  Google Scholar 

  • National Centre for Immunisation Research and Surveillance. Rotavirus vaccines for Australian children | NCIRS Fact Sheet. 2013. http://www.ncirs.edu.au/assets/provider_resources/fact-sheets/rotavirus-fact-sheet.pdf.

    Google Scholar 

  • Patel MM, López-Collada VR, Bulhões MM, De Oliveira LH, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med. 2011;364:2283–92.

    Article  CAS  PubMed  Google Scholar 

  • Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11–22.

    Article  CAS  PubMed  Google Scholar 

  • Soares-Weiser K, Goldberg E, Tamimi G, Pitan O, Leibovici L. Rotavirus vaccine for preventing diarrhoea. Cochrane Database Syst Rev. 2004;(1):CD002848.

    Google Scholar 

  • Vesikari T, Matson DO, Dennehy P, Van Damme P, et al. Safety and efficacy of a pentavalent human–bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23–33.

    Article  CAS  PubMed  Google Scholar 

  • WHO. Rotavirus vaccine and intussusception: report from an expert consultation. Wkly Epidemiol Rec. 2011;86:317–21.

    Google Scholar 

  • World Health Organization. Rotavirus vaccines. WHO position paper—January 2013. Wkly Epidemiol Rec. 2013;88:49–64.

    Google Scholar 

2.15 Tick-Borne Encephalitis (TBE)

2.16 Tuberculosis

  • Brewer T, Colditz G. Bacille Calmette-Guérin vaccination for the prevention of tuberculosis in health care workers. Clin Infect Dis. 1995;20:136–42.

    Article  CAS  PubMed  Google Scholar 

  • Colditz G, Brewer T, Berkey C, Wilson M, Burdick E, Fineberg H. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994;271:698–702.

    Article  CAS  PubMed  Google Scholar 

  • Cruz A, Starke J, Lobato M. Old and new approaches to diagnosing and treating latent tuberculosis in children in low-incidence countries. Curr Opin Pediatr. 2014;26:106–13.

    Article  PubMed  PubMed Central  Google Scholar 

  • Denholm J, Thevarajan I. Tuberculosis and the traveller: evaluating and reducing risk through travel consultation. J Travel Med. 2016;23.

    Article  PubMed  Google Scholar 

  • Harrop T, Aird J, Thwaites G. How to minimise risk of acquiring tuberculosis when working in a high prevalence setting: a guide for healthcare workers. BMJ. 2011;342:d1544.

    Article  PubMed  Google Scholar 

  • National Tuberculosis Advisory Committee Update October 2012. The BCG vaccine: information and recommendations for use in Australia. Commun Dis Intell Q Rep. 2013;37:E65–72.

    Google Scholar 

  • Ritz N, Tebruegge M, Camacho-Badilla K, Haeusler G, Connell T, Curtis N. To TST or not to TST: is tuberculin skin testing necessary before BCG immunisation in children? Vaccine. 2012;30:1434–6.

    Article  PubMed  Google Scholar 

  • Roy A, Eisenhut M, Harris R, Rodrigues L, Sridhar S, Habermann S, Snell L, Mangtani P, Adetifa I, Lalvani A, Abubakar I. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ. 2014;349:g4643.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • WHO. Global tuberculosis report 2017. Geneva: World Health Organization; 2017.

    Google Scholar 

2.17 Typhoid

  • Acharya VI, Lowe CU, Thapa R, Gurubacharya VL, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med. 1987;317:1101–4.

    Article  CAS  PubMed  Google Scholar 

  • CATMAT. Statement on international travellers and typhoid: an advisory committee statement. 2014. http://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-98-2014-eng.pdf.

    Google Scholar 

  • Connor BA, Schwartz E. Typhoid and paratyphoid fever in travellers. Lancet Infect Dis. 2005;5:623–8.

    Article  PubMed  Google Scholar 

  • Ferreccio C, Levine MM, Rodriguez H, Contreras R. Comparative efficacy of two, three or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis. 1989;159:766–9.

    Article  CAS  PubMed  Google Scholar 

  • Howlader DR, Koley H, Maiti S, Bhaumik U, Mukherjee P, Dutta S. A brief review on the immunological scenario and recent developmental status of vaccines against enteric fever. Vaccine. 2017;35(47):6359–66.

    Article  CAS  PubMed  Google Scholar 

  • Judd MC, Mintz ED. Typhoid and Paratyphoid fever [updated May 31 2017]. In: Centers for Disease Control and Prevention. CDC Yellow Book 2018: Health Information for International Travel. New York: Oxford University Press; 2017. https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/typhoid-paratyphoid-fever. Accessed 24 Dec 2018.

    Google Scholar 

  • Klugman K, Gilbertson IT, Kornhoff HJ, Robbins JB, et al. Protective activity of Vi polysaccharide vaccine against typhoid fever. Lancet. 1987;2:1165–9.

    Article  CAS  PubMed  Google Scholar 

  • Lebacq E. Comparative tolerability and immunogenicity of Typherix or Typhim Vi in healthy adults: 0,12-month and 0, 24-month administration. BioDrugs. 2001;15(Suppl 1):5–12.

    Article  CAS  PubMed  Google Scholar 

  • Levine MM, Ferreccio C, Abrego P, Martin OS, et al. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine. 1999;17(Suppl 2):22–7.

    Article  Google Scholar 

  • Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2018;(5):CD001261.

    Google Scholar 

  • Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale VV, Ramani E, Kim YE, Park JK, Wierzba TF. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health. 2014;2(10):e570–80.

    Article  PubMed  Google Scholar 

  • National Notifiable Diseases Surveillance System, Australian Government Department of Health. http://www9.health.gov.au/cda/source/rpt_3_sel.cfm. Accessed Jun 2018.

  • Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Bhattacharya SK, et al. A study of typhoid fever in five Asian countries: disease burden and implications for control. Bull World Health Organ. 2008;86:260–8.

    Article  PubMed  PubMed Central  Google Scholar 

  • Seqirus Pty Ltd. Vivotif oral prescribing information. Aust R 158130. Date of approval 17 Feb 2017.

    Google Scholar 

  • Stubi CL, Landry PR, Petignat C, Bille J, et al. Compliance to live oral Ty21a typhoid vaccine, and its effect on viability. J Travel Med. 2000;7(3):133–7.

    Article  CAS  PubMed  Google Scholar 

  • Waddington CS, Darton TC, Pollard AJ. The challenge of enteric fever. J Infect. 2014;68(Suppl 1):S38–50.

    Article  PubMed  Google Scholar 

  • Wain J, Hendriksen RS, Mikoleit ML, Keddy KH, Ochiai RL. Typhoid fever. Lancet. 2015;385(9973):1136–45.

    Article  PubMed  Google Scholar 

  • World Health Organization. Typhoid vaccines. WHO position paper. Wkly Epidemiol Rec. 2008;83(6):49–60.

    Google Scholar 

  • Zuckerman JN, Hatz C, Kantele A. Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines. Expert Rev Vaccines. 2017;16(10):1029–43.

    Article  CAS  PubMed  Google Scholar 

2.18 Varicella Zoster Virus

  • Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on immunization practices for use of herpes zoster vaccines. Morb Mortal Wkly Rep. 2018;67(3):103–8.

    Google Scholar 

  • Chaves SS, Gargiullo P, Zhang JX, Civen R, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med. 2007;356:1121–9.

    Article  CAS  PubMed  Google Scholar 

  • Dhillon S, Curran M. Live attenuated measles, mumps, rubella, and varicella zoster virus vaccine (Priorix-Tetra). Paediatr Drugs. 2008;10:337–47.

    Article  PubMed  Google Scholar 

  • Cunningham AL, Lal H, Koval M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–32.

    Article  CAS  PubMed  Google Scholar 

  • Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on immunization practices for use of herpes zoster vaccines. Morb Mortal Wkly Rep. 2018;67:103–8.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–96.

    Article  PubMed  Google Scholar 

  • Macartney K, Burgess M. Varicella vaccination in Australia and New Zealand. J Infect Dis. 2008;197(Suppl 2):S191–5.

    Article  PubMed  Google Scholar 

  • Marin M, Guris D, Chaves S, Schmid S, Seward J. Prevention of varicella: recommendations of the Advisory Committee on immunization practices (ACIP). Morb Mortal Wkly Rep. 2007;56(RR-4):1–40.

    Google Scholar 

  • Marin M, Meissner H, Seward J. Varicella prevention in the United States: a review of successes and challenges. Pediatrics. 2008;122(3):e744–51.

    Article  PubMed  Google Scholar 

  • National Centre for Immunisation Research & Surveillance. Zoster vaccine for Australian adults: factsheet. August 2017.

    Google Scholar 

  • Sartori AM. A review of the varicella vaccine in immunocompromised individuals. Int J Infect Dis. 2004;8:259–70.

    Article  PubMed  Google Scholar 

  • Seward JF, Watson BM, Peterson CL, Mascola L, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA. 2002;287:606–11.

    Article  PubMed  Google Scholar 

  • Therapeutic Guidelines. Antibiotic (eTG June 2019 edition). Melbourne: Therapeutic Guidelines Limited; 2019.

    Google Scholar 

  • Turner DP, McGuinness SL, Cohen J et al. Use of pre-travel vaccine-preventable disease serology as a screening tool to identify patients in need of pre-travel vaccination: a retrospective audit. J Travel Med. 2017;24(3). tax011.

    Google Scholar 

2.19 Yellow Fever

  • Ahuka-Mundeke S, Casey RM, Harris JB, Dixon MG, Nsele PM, Kizito GM, et al. Immunogenicity of fractional-dose vaccine during a Yellow Fever outbreak—preliminary report. N Engl J Med. 2018. [Epub ahead of print]. https://doi.org/10.1056/NEJMoa1710430

    Article  PubMed  Google Scholar 

  • Australian Government Department of Health. National Guidelines for Yellow Fever Vaccination Centres and Providers. Australia: Canberra; 2018. http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-bio-yellow-fever.htm. Accessed 30 Nov 2018.

    Google Scholar 

  • Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis. 2007;44(6):850–6.

    Article  PubMed  Google Scholar 

  • Barwick R. History of thymoma and yellow fever vaccination. Lancet. 2004;364(9438):936.

    Article  Google Scholar 

  • Campi-Azevedo AC, Costa-Pereira C, Antonelli LR, Fonseca CT, Teixeira-Carvalho A, Villela-Rezende G, et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Hum Vaccin Immunother. 2016;12(2):491–502.

    Article  PubMed  Google Scholar 

  • Collaborative Group for Studies on Yellow Fever Vaccination. Duration of post-vaccination immunity against yellow fever in adults. Vaccine. 2014;32(39):4977–84.

    Article  CAS  Google Scholar 

  • Cottin P, Niedrig M, Domingo C. Safety profile of the yellow fever vaccine Stamaril(R): a 17-year review. Expert Rev Vaccines. 2013;12(11):1351–68.

    Article  CAS  PubMed  Google Scholar 

  • da Costa-Rocha IA, Campi-Azevedo AC, Peruhype-Magalhaes V, Coelho-Dos-Reis JG, Fradico JRB, Souza-Lopes T, et al. Duration of humoral and cellular immunity 8 years after administration of reduced doses of the 17DD-yellow fever vaccine. Front Immunol. 2019;10:1211.

    Google Scholar 

  • Garske T, Van Kerkhove MD, Yactayo S, Ronveaux O, Lewis RF, Staples JE, et al. Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med. 2014;11(5):e1001638.

    Article  PubMed  PubMed Central  Google Scholar 

  • Gershman M, Staples JE. Yellow fever. In: Centers for Disease Control and Prevention. CDC Yellow Book 2018: Health Information for International Travel. New York: Oxford University Press; 2017. https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/yellow-fever. Accessed 20 Aug 2019.

    Google Scholar 

  • Gotuzzo E, Yactayo S, Cordova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89(3):434–44.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hamer DH, Angelo K, Caumes E, van Genderen PJJ, et al. Fatal Yellow fever in travelers to Brazil, 2018. Morb Mortal Wkly Rep. 2018;67(11):340–1.

    Article  Google Scholar 

  • Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine. 2005;23(25):3256–63.

    Article  PubMed  Google Scholar 

  • Lindsey NP, Schroeder BA, Miller ER, Braun MM, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26:6077–82.

    Article  CAS  PubMed  Google Scholar 

  • Marfin AA, Eidex RS, Kozarsky PE, Cetron MS. Yellow fever and Japanese encephalitis vaccines: indications and complications. Infect Dis Clin North Am. 2005;19(1):151–68.

    Article  PubMed  Google Scholar 

  • Vellozzi C, Mitchell T, Miller E, Casey CG, Eidex RB, Hayes EB. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004. Am J Trop Med Hyg. 2006;75(2):333–6.

    Article  PubMed  Google Scholar 

  • Monath TP. Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg. 2010;82:919–21.

    Article  PubMed  PubMed Central  Google Scholar 

  • Monath TP, Cetron MS. Prevention of yellow fever in persons travelling to the tropics. Clin Infect Dis. 2002;34:1369–78.

    Article  PubMed  Google Scholar 

  • Monath TP, Cetron MS, McCarthy K, Nichols R, Archambault WT, Weld L, et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin. 2005;1(5):207–14.

    Article  PubMed  Google Scholar 

  • Monath TP, Vasconcelos PF. Yellow fever. J Clin Virol. 2015;64:160–73.

    Article  PubMed  Google Scholar 

  • Roukens AHE, van Halem K, de Visser AW, Visser LG. Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled, noninferiority trial. Ann Intern Med. 2018;169(11):761–5. https://doi.org/10.7326/M18-1529.

    Article  PubMed  Google Scholar 

  • Sidibe M, Yactayo S, Kalle A, Sall AA, Sow S, Ndoutabe M, et al. Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali. Trans R Soc Trop Med Hyg. 2012;106(7):437–44.

    Article  CAS  PubMed  Google Scholar 

  • Staples JE, Bocchini JA Jr, Rubin L, Fischer M, Centers for Disease C, Prevention. Yellow Fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. Morb Mortal Wkly Rep. 2015;64(23):647–50.

    Google Scholar 

  • Tanizaki R, Ujiie M, Hori N, Kanagawa S, Kutsuna S, Takeshita N, et al. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period. J Travel Med. 2016;23(3). taw012.

    Article  PubMed  Google Scholar 

  • Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009;48(5):659–66.

    Article  PubMed  Google Scholar 

  • World Health Organization. International travel and health. Geneva: World Health Organization; 2011.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Professor of Medicine, Infectious Diseases Physician University of Melbourne, Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia

    Joseph Torresi

  2. Knox Private Hospital, Melbourne, VIC, Australia

    Joseph Torresi

  3. Epworth Eastern Hospital, Melbourne, VIC, Australia

    Joseph Torresi

  4. Austin Hospital, Melbourne, VIC, Australia

    Joseph Torresi

  5. Infectious Diseases Physician, Department of Infectious Diseases, The Alfred Hospital and Monash University, Melbourne, VIC, Australia

    Sarah McGuinness

  6. Lecturer, Infectious Disease Epidemiology Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia

    Sarah McGuinness

  7. Professor of Medicine, Infectious Diseases Physician, Head of Infectious Disease Epidemiology, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia

    Karin Leder

  8. Head of Travel Medicine and Immigrant Health, Victorian Infectious Disease Service, Royal Melbourne Hospital Peter Doherty, Institute for Infection and Immunity, Melbourne, VIC, Australia

    Karin Leder

  9. Associate Professor, Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC, Australia

    Daniel O’Brien

  10. Department of Infectious Diseases, University Hospital Geelong, Geelong, VIC, Australia

    Daniel O’Brien

  11. Associate Professor, Nossal Institute for Global Health, School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia

    Tilman Ruff AO

  12. International Medical Advisor, Australian Red Cross (1996–2019), Founding Head of Travel Medicine at Fairfield and Royal Melbourne Hospitals, Melbourne, VIC, Australia

    Tilman Ruff AO

  13. Paediatrician, Infectious Diseases Physician, Consultant in Emergency Medicine, Director of Paediatric Education, , Royal Children’s Hospital Melbourne, Honorary Clinical Associate Professor, University of Melbourne, Melbourne, VIC, Australia

    Mike Starr

  14. Infectious Diseases Physician, Public Health Physician and Senior Research Fellow, The Austin Hospital, The Royal Melbourne Hospital, and The University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia

    Katherine Gibney

Authors
  1. Joseph Torresi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah McGuinness
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karin Leder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel O’Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tilman Ruff AO
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mike Starr
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Katherine Gibney
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Torresi, J. et al. (2019). Immunisation. In: Manual of Travel Medicine. Springer, Singapore. https://doi.org/10.1007/978-981-13-7252-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-7252-0_2

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-7251-3

  • Online ISBN: 978-981-13-7252-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation